<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449306</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-01-2354-JS-CTIL</org_study_id>
    <nct_id>NCT00449306</nct_id>
  </id_info>
  <brief_title>Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques</brief_title>
  <official_title>Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CVpath Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lipid-rich atherosclerotic plaques, or &quot;vulnerable plaques&quot; are prone to rupture, causing
      local intravascular thrombosis, with subsequent grave clinical consequences. Atherosclerotic
      plaques normally removed during surgery, and peripheral blood samples will be studied to
      achieve the following objectives:

      &quot;1&quot; Define histological features of the vulnerable plaque, analyze its physical
      characteristics, and investigate selected gene expression.

      &quot;2&quot; Study biomarkers of inflammation in conjunction with the presence of vulnerable plaques.

      &quot;3&quot; Explore the potential role of infection in atherogenesis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To uncover mechanisms of cardiovascular diseases</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Aortic Aneurysm</condition>
  <condition>Peripheral Vascular Diseases</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue for RNA extraction (frozen); Tissue for histological analysis (formalin fixation);
      Plasma for CV biomarkers (frozen)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinic patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of symptomatic carotid stenosis exceeding 60%(TIAs or stroke within the last
             6 months), and asymptomatic carotid artery stenosis (presenting with progressive
             carotid stenosis, exceeding 70%)

          -  Abdominal aortic aneurysm, and aortic occlusive disease

          -  Peripheral occlusive or aneurysmal disease

        Exclusion Criteria:

          -  Non-compliant patients, incapable of granting approval by informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Schneiderman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Vascular Surgery, Sheba Medical Center, Tel Hashomer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center, Tel Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2007</study_first_submitted>
  <study_first_submitted_qc>March 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2007</study_first_posted>
  <last_update_submitted>October 23, 2016</last_update_submitted>
  <last_update_submitted_qc>October 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Carotid plaque</keyword>
  <keyword>Abdominal aortic aneurysm</keyword>
  <keyword>Vulnerable plaque</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Intraplaque hemorrhage</keyword>
  <keyword>Carotid artery atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

